Piper Jaffray Reiterates Overweight On Nektar Therapeutics; Sees Upside From Current Levels
Piper Jaffray analyst Joshua Schimmer came out with a research note on Nektar Therapeutics (NASDAQ:NKTR), following the company’s fourth-quarter results posting revenue of $19.5 million compared to Jaffray’s estimate of $15 million, and EPS of ($0.35) compared to Jaffray’s estimate of ($0.30).
Schimmer wrote, “In March, the company will report topline results from the P3 BEACON study of NKTR-102 (Pegylated irinotecan) for triplenegative breast cancer. Based on a strong monotherapy profile and a mechanism which isn’t part of the current standard of care, we believe success is likely. The company has a collection of other late-stage and emerging assets which should help protect the downside should results not be robust.”
Furthermore, “We see upside from current levels based on the totality of the company’s late-stage programs (Movantik with AZN, BAX-855 with BAX, inhaled Amikacin with Bayer, NKTR-102). We’re currently less enamoured with the rest of the pipeline, however. We’re cautious on NKTR-181 for pain, which is advancing into P3 this year, 171 for neuropathic pain and the ‘214 immuno-oncolsee upside from current levelsogy drug (i.e the rest of the pipeline). For a pegylation platform company, we’d prefer to see less speculative programs in lieu of lower-risk, more niche/specialty opportunities, although it’s possible those low hanging friut might have all already been picked.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joshua Schimmer has a total average return of 19.6% and a 73.0% success rate. Schimmer has a 35.6% average return when recommending NKTR, and is ranked #187 out of 3483 analysts.